 Aridis Pharmaceuticals, Inc. Nasdaq: ARDS, a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate results for the first quarter ended March 31, 2020. 